Akoya Biosciences, Inc.

NasdaqGS:AKYA Stock Report

Market Cap: US$232.4m

Akoya Biosciences Future Growth

Future criteria checks 1/6

Akoya Biosciences is forecast to grow earnings and revenue by 55.6% and 13.6% per annum respectively. EPS is expected to grow by 59.4% per annum. Return on equity is forecast to be -9.1% in 3 years.

Key information

55.6%

Earnings growth rate

59.4%

EPS growth rate

Life Sciences earnings growth16.3%
Revenue growth rate13.6%
Future return on equity-9.1%
Analyst coverage

Good

Last updated12 Mar 2024

Recent future growth updates

Recent updates

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Akoya Biosciences and AstraZeneca ink collaboration agreement

Jun 04

Earnings and Revenue Growth Forecasts

NasdaqGS:AKYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026163-11-165
12/31/2025140-26-159
12/31/2024116-41-32-159
12/31/202397-63-55-51N/A
9/30/202391-71-59-55N/A
6/30/202385-76-61-54N/A
3/31/202379-73-62-55N/A
12/31/202275-71-61-53N/A
9/30/202270-69-57-49N/A
6/30/202264-63-57-51N/A
3/31/202260-51-55-50N/A
12/31/202155-44-41-36N/A
9/30/202152-34-37-32N/A
6/30/202148-28-24-21N/A
3/31/202144-28-13-10N/A
12/31/202042-22-10-7N/A
12/31/201942-18-17-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKYA's revenue (13.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: AKYA's revenue (13.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AKYA is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.